Abstracts tagged "Scleroderma"

Abstract Number: 1531 • ACR Convergence 2022
Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Three-Year Data from SENSCIS-ON
Yannick Allanore¹, Madelon Vonk², Oliver Distler³, Arata Azuma⁴, Maureen Mayes⁵, Alexandra James⁶, Veronika Kohlbrenner⁷, Margarida Alves⁸, Dinesh Khanna⁹ and Kristin Highland¹⁰, ¹Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ²Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁴Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, ⁵Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, ⁶Elderbrook solutions GmbH, Bietigheim-Bissingen, Germany, Bietigheim-Bissingen, Germany, ⁷Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁹Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹⁰Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH
Background/Purpose: In the randomized placebo-controlled SENSCIS trial in patients with SSc-ILD, nintedanib reduced the rate of decline in forced vital capacity (FVC) (mL/year) over 52…
Abstract Number: 2163 • ACR Convergence 2022
Lipid Profile in Scleroderma Patients and the Associations of Its Changes with Disease-specific Features
Sabina Oreska¹, Hana Storkanova¹, Maja Spiritovic², Barbora Hermankova², Michal Vrablík³, Karel Pavelka⁴, Jiří Vencovský⁵, Ladislav Šenolt⁵, Radim Becvar¹ and Michal Tomcik¹, ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Rheumatology, Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³3rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Systemic sclerosis (SSc) is characterized by skin and organ involvement and chronic disease course. Systemic inflammation, involvement of the gastrointestinal tract, and glucocorticoid treatment…
Abstract Number: 0712 • ACR Convergence 2022
Disease Prevalence and Patient Characteristics in Patients with and Without Scleroderma Renal Crisis – A National US-based Inpatient Comparison Study
Anila Hussain¹, Pushti Khandwala² and Thais Moldovan³, ¹Crozer Chester Medical Center, Glen Mills, PA, ²Einstein Medical Center Philadelphia, Glen Mills, PA, ³Rheumatology Care Center, Media, PA
Background/Purpose: Scleroderma renal crisis is a rare complication of Systemic Sclerosis (SSc) with high mortality and morbidity. Most patients present with acute symptomatic increase in…
Abstract Number: 1170 • ACR Convergence 2022
Systemic Sclerosis Dermal Fibroblast-derived Exosomes Trigger a Type 1 Interferon Rresponse in Keratinocytes Through TBK1
Jessica Bryon¹, Christopher Wasson¹, Rebecca Ross¹, Elton Zeqiraj¹ and Francesco Del Galdo², ¹University of Leeds, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: Elevated Type I IFN response is present in blood and affected tissues in systemic sclerosis (SSc) and correlates with disease activity and response to…
Abstract Number: 1532 • ACR Convergence 2022
The Primary Cardiomyopathy of Systemic Sclerosis on Cardiovascular Magnetic Resonance Imaging
sanya Chhikara¹, Adinan Kanda², mohamed Ismail², Fredrick Ogugua², Rejowana Rouf², khaled Ismail², Parag Bawaskar², Jerry Molitor² and Chetan Shenoy², ¹University of Minnesota, New York, NY, ²University of Minnesota, Minneapolis, MN
Background/Purpose: Cardiac disease in systemic sclerosis (SSc) may be primary or secondary to coronary artery disease, pulmonary, or renal disease. The prevalence of the primary…
Abstract Number: 2164 • ACR Convergence 2022
Profibrotic Alveolar Macrophages as a Potential Biomarker in Systemic Sclerosis-associated Interstitial Lung Disease
Nikolay Markov¹, Karolina Senkow¹, Anthony Esposito², Jonathan Puchalski³, Mridu Gulati³, Erica Herzog³, Danielle Antin-Ozerkis⁴, Mary Carns⁵, Alyssa Williams⁶, Nic Page⁶, Alexander Misharin¹ and Monique Hinchcliff⁷, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Brigham and Women's Hospital, Department of Medicine, Boston, MA, ³Yale School of Medicine, New Haven, CT, ⁴Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, ⁵Northwestern University Division of Rheumatology, Chicago, IL, ⁶Yale University, New Haven, CT, ⁷Yale School of Medicine, Westport, CT
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of death in patients with systemic sclerosis (SSc). Previously, profibrotic monocyte-derived alveolar macrophages (MoAM) expressing (SPP1,…
Abstract Number: 0940 • ACR Convergence 2022
Effect of an 8-week Tailored Physical Therapy Program on Sexual Function in Women with Systemic Sclerosis and Idiopathic Inflammatory Myopathies: A Pilot Controlled Study
Barbora Hermankova¹, Maja Spiritovic¹, Sabina Oreska², Hana Storkanova², Karel Pavelka³, Ladislav Šenolt⁴, Jiří Vencovský⁴, Radim Becvar² and Michal Tomcik², ¹Institute of Rheumatology, Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Systemic rheumatic diseases like systemic sclerosis (SSc) and idiopathic inflammatory myopathies (IIM) may affect all aspects of life, including sexual health. However, no non-pharmacological…
Abstract Number: 1171 • ACR Convergence 2022
Distinct Immune Cell Subsets in Systemic Sclerosis-related Interstitial Lung Disease
Phan Saligrama¹, Erin Wilfong², Elise Rizzi³, Leslie Crofford² and Peggy Kendall¹, ¹Washington University, Saint Louis, MO, ²Vanderbilt University Medical Center, Nashville, TN, ³Pennsylvania State University, Hershey, PA
Background/Purpose: The pathogenesis of systemic sclerosis is not well understood. The key differences between immune cell compartments in scleroderma with and without interstitial lung disease…
Abstract Number: 1535 • ACR Convergence 2022
Frequency of Arrhythmias, Abnormal Electrocardiography and Sudden Cardiac Death in Systemic Sclerosis: A Systematic Review and Meta-analysis
Jessica Fairley¹, Laura Ross², Alannah Quinlivan³, Dylan Hansen⁴, Elizabeth Paratz⁵, Wendy Stevens⁴, Peter M Kistler⁶, Andre La Gerche⁷ and Mandana Nikpour⁸, ¹The University of Melbourne, Melbourne, Australia, ²The University of Melbourne at St. Vincent's Hospital, Brunswick, Australia, ³St Vincent's Hospital Melbourne and the University of Melbourne, Melbourne, Australia, ⁴St Vincent's Hospital Melbourne, Melbourne, Australia, ⁵The Baker Institute; St Vincent's Hospital Melbourne, Melbourne, Australia, ⁶The Baker Heart and Diabetes Institute; The University of Melbourne; Monash University, Melbourne, Australia, ⁷The Baker Heart and Diabetes Institute; The University of Melbourne, Melbourne, Australia, ⁸The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia
Background/Purpose: Scleroderma (SSc) Heart Involvement (SHI) is an under recognised complication of SSc and may manifest as arrhythmias or sudden cardiac death(SCD). The incidence of…
Abstract Number: 2166 • ACR Convergence 2022
Inflammatory Arthritis in an Australian Scleroderma Cohort – Patient Characteristics, Associations and Treatments
Eric Schwender¹, Dylan Hansen², Wendy Stevens², Laura Ross³, Nava Ferdowsi², Susanna Proudman⁴, Jenny Walker⁵, Jo Sahhar⁶, Gene-Siew Ngian⁷, Lauren Host⁸, Gabor Major⁹, Mandana Nikpour¹⁰ and Kathleen Morrisroe², ¹Royal College of Surgeons, Dublin, Ireland, ²St Vincent's Hospital Melbourne, Melbourne, Australia, ³The University of Melbourne at St. Vincent's Hospital, Brunswick, Australia, ⁴Rheumatology Unit, Royal Adelaide Hospital, and Discipline of Medicine, University of Adelaide, Adelaide, Australia, ⁵Royal Adelaide Hospital, Adelaide, Australia, ⁶Monash Health, Melbourne, Australia, ⁷Melbourne Health, Northcote, Australia, ⁸Fiona Stanley Hospital, London, United Kingdom, ⁹Hunter New England Health Service, Rankin Park - Newcastle, New South Wales, Australia, ¹⁰The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia
Background/Purpose: To characterise a cohort of Australian scleroderma patients with inflammatory arthritis including patient characteristics, autoantibody profile, therapy and impact on function and quality of…
Abstract Number: 1046 • ACR Convergence 2022
Scleroderma Heart Disease
Mohamed Talaat¹, Vivien Hsu² and Daniel Shindler³, ¹Rutgers Robert Wood Johnson University Hospital, North Brunswick, NJ, ²Rutgers-RWJ Medical School, South Plainfield, NJ, ³Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ
Background/Purpose: Scleroderma heart involvement (SHI) is the 3rd leading cause of death in systemic sclerosis (SSc) [1] following interstitial lung disease (ILD) & pulmonary arterial…
Abstract Number: 1172 • ACR Convergence 2022
Transcription Analysis of Macrophages Reveals Important Changes Induced by Systemic Sclerosis Fibroblasts
Juan-Pablo Zertuche¹, Taha Dinc², Fatima El Adili³, Giovanni Ligresti¹ and Andreea Bujor¹, ¹Boston University, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³Boston University School of Medicine, Revere, MA
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune connective tissue disease characterized by immune system activation, endothelial dysfunction and widespread tissue fibrosis. Activation of the monocyte/macrophage…
Abstract Number: 1538 • ACR Convergence 2022
Decreased Prevalence of Autoimmune Connective Tissue Diseases in Type 1 and Type 2 Diabetes
Aya abugharbyeh, Sadik Khuder and bashar Kahaleh, University of Toledo, Toledo, OH
Background/Purpose: Evidence suggest that autoimmune diseases tend to coexist at a higher rate than expected, reflecting a common pathogenetic pathway. However, data sets have shown…
Abstract Number: 2168 • ACR Convergence 2022
A Novel Pharmaco-Interventional Approach for the Treatment of Refractory Digital Ischemia in Systemic Sclerosis – Percutaneous Revascularization Combined with Intravenous Vasodilatory Therapy
Lily Romero Karam¹, Kevin Honan¹, Salman Arain¹ and Maureen Mayes², ¹University of Texas Health Science Center at Houston, Houston, TX, ²Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX
Background/Purpose: The combination of Raynaud´s Phenomenon (RP) and vasculopathy, characterized by intimal proliferation and fibrosis, endothelial dysfunction, and smooth-muscle activation, can lead to severe digital…
Abstract Number: 1047 • ACR Convergence 2022
A Novel Prediction Tool for Progression of Systemic Sclerosis-Interstitial Lung Disease Despite Treatment with Immunosuppression
Elizabeth Volkmann¹, Holly Wilhalme¹, Grace Kim¹, Jonathan Goldin¹, Shervin Assassi², Masataka Kuwana³, Donald Tashkin¹ and Michael roth¹, ¹University of California Los Angeles, Los Angeles, CA, ²McGovern Medical School, University of Texas, Houston, TX, ³Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Systemic sclerosis-interstitial lung disease (SSc-ILD) is the leading cause of SSc-related death. While some patients respond favorably to treatment with immunosuppression, a subset of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].